Masimo (MASI) reported another period of losses, with annual net losses worsening at an average rate of 53.1% over the past five years. While revenue is expected to grow just 6.5% per year versus 10.5% for the broader US market, analysts see a turnaround in earnings with a projected 12.03% annual growth and a path to profitability within three years. For investors, this mix of underwhelming revenue growth and improving profitability prospects presents a complicated outlook heading into the next results cycle.

See our full analysis for Masimo.

Next, we’ll see how these numbers align with the stories investors and analysts are telling, and whether the latest results support or challenge those prevailing narratives.

See what the community is saying about Masimo

Analysts expect Masimo's profit margins to rise sharply, from -12.5% today to 15.9% in three years, a major shift that would take the company from steep losses into strong profitability.

According to the analysts' consensus view, this projected margin jump is driven by new leadership hires and operational efficiency gains, alongside fresh product innovation and expansion into high-growth markets.

Moves like expanding specialty sales teams and launching next-generation monitors should help increase market share in key segments, which backs up the expectation for sustained margin growth.

At the same time, diversification into recurring revenue streams through at-home monitoring and telehealth is intended to reduce volatility in earnings, supporting the push to positive margins despite current losses.

Consensus narrative points to operational changes and product strategy as key to reversing losses. See what the full panel of analysts expects in our detailed balance of bull and bear perspectives: ???? Read the full Masimo Consensus Narrative.

Masimo’s share price of $142.14 trades at a discount to its DCF fair value of $157.25, suggesting the market price may not fully reflect long-term recovery potential.

Under the analysts' consensus view, Masimo is considered attractively valued on some metrics like price-to-sales relative to peers, yet remains more expensive than the US medical equipment industry average. This presents a nuanced picture for valuation-focused investors.

The current discount versus fair value supports the upside case if profitability goals are hit, but trading at a relative premium to the industry highlights the market's confidence as well as raised expectations for performance.

With analysts targeting $186.57 per share, the gap between today's price and consensus upside hinges on Masimo delivering against margin, revenue, and innovation forecasts in the next three years.

Despite positive forecasts, Masimo is not currently in a strong financial position, with losses worsening by 53.1% per year over the last five years. This serves as a stark reminder of ongoing balance sheet risk.

The analysts' consensus narrative underscores that sustained losses, exposure to tariffs, and dependence on capital-intensive hospital contracts could create persistent headwinds for free cash flow and earnings stability, challenging bullish profitability predictions.

Heavy reliance on large, lumpy hospital contracts and early-stage expansion into new monitoring markets adds unpredictability, increasing vulnerability to disruptions.

Tariff pressures and the shift to operating lease accounting may also weigh on margins and revenue visibility, emphasizing why a cautious approach is still warranted despite the expected earnings improvement.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Masimo on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Got a unique angle on the numbers? Shape your own view in just a few minutes and make your perspective count. Do it your way

A great starting point for your Masimo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

While Masimo aims for a turnaround, ongoing losses, balance sheet risks, and reliance on unpredictable contracts continue to weigh on its financial stability.

If robust financial health is your priority, use our solid balance sheet and fundamentals stocks screener (1979 results) to quickly identify companies with stronger balance sheets built to navigate uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MASI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com